Skip to main content
. 2024 Jun 28;13(10):2105–2121. doi: 10.1007/s40121-024-01007-z

Fig. 2.

Fig. 2

Integrated CDI recurrence rate in patients who received at least one dose of VOS in ECOSPOR III and/or ECOSPOR IV